Predictive Oncology Inc. (NASDAQ:POAI) Sees Significant Growth in Short Interest

Predictive Oncology Inc. (NASDAQ:POAI) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 161,300 shares, an increase of 56.8% from the September 30th total of 102,900 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average trading volume of 2,710,000 shares, the days-to-cover ratio is presently 0.1 days.

Predictive Oncology Stock Performance

Shares of POAI traded down $0.09 during trading hours on Tuesday, hitting $0.75. The stock had a trading volume of 148,489 shares, compared to its average volume of 1,400,028. Predictive Oncology has a 12-month low of $0.55 and a 12-month high of $3.76. The firm has a market cap of $3.08 million, a P/E ratio of -0.21 and a beta of 1.13. The company’s fifty day simple moving average is $0.80 and its 200 day simple moving average is $1.12.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) EPS for the quarter. The firm had revenue of $0.28 million for the quarter. Predictive Oncology had a negative return on equity of 200.06% and a negative net margin of 802.69%. As a group, sell-side analysts predict that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on shares of Predictive Oncology in a research report on Monday, August 19th. They set a “buy” rating and a $3.00 price target for the company.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.